Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Malignancy and systemic lupus erythematosus.

Sasha Bernatsky1, Ann Clarke, Rosalind Ramsey-Goldman

  • 1Northwestern University, Division of Rheumatology, Arthritis, Ward 3-315, 303 East Chicago Avenue, Chicago, IL 60611-3088, USA.

Current Rheumatology Reports
|July 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Vitro Fertilization is Essential Healthcare for Patients With Rheumatic Disease.

ACR open rheumatology·2026
Same author

Bias due to interval censored outcomes in a study of flare risk after hydroxychloroquine taper/cessation in systemic lupus erythematosus.

Journal of clinical epidemiology·2026
Same author

C4b-binding protein as an antigenic target in the pathogenesis of antiphosphatidylethanolamine autoantibodies.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

A highly prevalent lupus risk haplotype increases IRF7-dependent induction of IFN-α, enhancing antiviral defense and exacerbating autoimmunity.

medRxiv : the preprint server for health sciences·2026
Same author

Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality.

Annals of the rheumatic diseases·2025
Same author

Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring.

Arthritis & rheumatology (Hoboken, N.J.)·2025

Systemic lupus erythematosus (SLE) patients may face a higher cancer risk, particularly non-Hodgkin's lymphoma. Further research is needed for solid tumor risks and treatment impacts, but standard cancer screenings are advised.

Area of Science:

  • Rheumatology
  • Oncology
  • Epidemiology

Background:

  • The link between systemic lupus erythematosus (SLE) and malignancy has been studied, with some cohort research suggesting an elevated cancer risk.
  • Previous studies indicate a potential increase in non-Hodgkin's lymphoma risk among SLE patients, though estimations lack precision.

Purpose of the Study:

  • To investigate the association between systemic lupus erythematosus (SLE) and the risk of developing malignancies.
  • To clarify the imprecise estimations of non-Hodgkin's lymphoma risk in SLE patients.
  • To assess the evidence regarding the risk of solid tumors in individuals with SLE.

Main Methods:

  • Review of existing cohort studies examining malignancy risk in SLE patients.
  • Analysis of data to estimate the risk of non-Hodgkin's lymphoma.

Related Experiment Videos

  • Evaluation of evidence for solid tumor risks in SLE.
  • Ongoing multicenter international research to further elucidate these associations and the role of therapies.

    • Main Results:

    • Cohort studies provide some support for an increased malignancy risk in SLE, but definitive interpretation is challenging.
    • Evidence suggests an increased risk of non-Hodgkin's lymphoma in SLE patients, but with imprecise risk estimation.
    • There is currently inadequate evidence to draw conclusions about the risk of solid tumors in SLE patients.

    Conclusions:

    • While an increased risk of malignancy, particularly non-Hodgkin's lymphoma, is suggested in SLE patients, further research is necessary for definitive conclusions, especially regarding solid tumors.
    • Ongoing international research aims to clarify these risks and the influence of treatments like cytotoxic or immunomodulatory therapy.
    • Standard cancer screening recommendations and risk factor minimization strategies for the general population should also be applied to individuals with SLE.